Friday, December 18, 2015

New Patent for PCM Technology

TrovaGene, Inc.(TROV), a developer of cell-free molecular diagnostics, on December 16, 2015 announced that the U.S. Patent and Trademark Office has issued Patent No 9,163,229 B2 entitled "Compositions, Methods and Kits for Isolating Nucleic Acids from Body Fluids Using Anion Exchange Media." This patent involves the methods for rapid separation, isolation of systemically derived cDNA, and purification of nucleic acids from urine samples using anion exchange media.

This new patent granted by the U.S Patent and Trademark Office, considerably boosts TrovaGene's intellectual property related to its Precision Cancer Monitoring (PCM) technology. Trovagene now has 87 patents issued and 61 patent applications pending in the U.S. and internationally. Of these, 59 issued patents are related to Trovagene's Precision Cancer Monitoring technology and the detection of cell free nucleic acids in bodily fluids.